Michelle Homan, DO
Pulmonary Disease · Kansas City, KSNPI 1780995720
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,092 of the $8,367 with a category attached, or 72.8%. Intuitive Surgical accounts for 91.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $7,409 and has fallen 99.8% since, to $17 in 2025.
Across 50 payments — averaging $167.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Boehringer Ingelheim$144
- La Jolla Pharmaceutical Company$132
- Mallinckrodt Hospital Products Inc.$75
- Sanofi$72
- AstraZeneca$62
- plus $255 from 10 others
What the payments were for
- Speaking & faculty fees$1502%
- Travel & lodging$1,25515%
- Food & beverage$6678%
- Education$6,09273%
- Gifts$2032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $7,627 |
| Boehringer Ingelheim | 8 | $144 |
| La Jolla Pharmaceutical Company | 3 | $132 |
| Mallinckrodt Hospital Products Inc. | 1 | $75 |
| Sanofi | 3 | $72 |
| AstraZeneca | 4 | $62 |
| GSK | 3 | $51 |
| Inogen, Inc. | 5 | $37 |
| Grifols USA, LLC | 2 | $33 |
| Amgen | 2 | $28 |
| AbbVie | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$6,000
- Da Vinci Surgical System$1,268
- DA VINCI SP$150
- GIAPREZA$111
How this compares
$8,367 in reported general payments places this provider in the 75th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $64,973 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $49,576 |
| Breo ElliptaFluticasone/Vilanterol | 89 | $45,722 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $40,811 |
| Spiriva RespimatTiotropium Bromide | 49 | $29,822 |
| Arnuity ElliptaFluticasone Furoate | 24 | $9,481 |
| EliquisApixaban | 16 | $9,425 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $5,593 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $5,362 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,876 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 14 | $4,512 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,761 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $2,662 |
| Azithromycin | 38 | $524 |
| Omeprazole | 12 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $51 | $125,052217 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $144 | $79,398119 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $62 | $43,57278 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Kansas City
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Heath LathamKansas City$15K
- Kyle BrownbackKansas City$15K
- Aman KhanKansas City$5K
- Damien StevensKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.